These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 8608539)
1. Urinary basic fetoprotein in the diagnosis and follow-up of patients with urothelial carcinoma. Kigure T; Wakayama Y; Satoh Y; Fujieda N; Yoshida K; Harada T Cancer; 1996 Apr; 77(8):1529-34. PubMed ID: 8608539 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702 [TBL] [Abstract][Full Text] [Related]
3. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma. Yao WJ; Chang CJ; Chan SH; Chow NH; Cheng HL; Tzai TS; Lin SN Anticancer Res; 1995; 15(6B):2819-23. PubMed ID: 8669871 [TBL] [Abstract][Full Text] [Related]
4. [Urinary tumor marker for urothelial cancer]. Ohtani M; Iwasaki A; Shiraiwa H Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491 [TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer]. Imamura M; Inoue K; Megumi Y; Nishimura M; Ohmori K; Nishimura K Hinyokika Kiyo; 2000 Oct; 46(10):705-9. PubMed ID: 11215195 [TBL] [Abstract][Full Text] [Related]
7. [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies]. Tsujii T; Yonese J; Kojima S; Tari K; Ishii M; Seino Y Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):829-34. PubMed ID: 1698231 [TBL] [Abstract][Full Text] [Related]
8. [Clinical studies on the measurement of urinary tissue polypeptide antigen (TPA) levels using Prolifigen TPA kit "Daiichi"-II in urothelial cancers]. Ohmori H; Ohashi T; Aso Y; Kumamoto Y; Hisazumi H; Shiraiwa Y; Kurita T; Shimazaki J; Ohkawa T; Ogawa H Hinyokika Kiyo; 1988 Dec; 34(12):2101-10. PubMed ID: 3071123 [TBL] [Abstract][Full Text] [Related]
9. [Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer]. Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M Hinyokika Kiyo; 2001 May; 47(5):307-10. PubMed ID: 11433749 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group]. Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522 [TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation on an enzyme immunoassay kit for basic fetoprotein (BFP). (1) Clinical usefulness of BFP]. Ishii M; Hattori N; Kato T; Mochizuki M; Kamidono S; Sawabu N; Kawada Y; Kawai T; Abe O; Ohkura H Gan To Kagaku Ryoho; 1988 Jul; 15(7):2107-13. PubMed ID: 2456039 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder. Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416 [TBL] [Abstract][Full Text] [Related]
13. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762 [TBL] [Abstract][Full Text] [Related]
14. The molecular signature for urothelial carcinoma of the upper urinary tract. Ho CL; Tzai TS; Chen JC; Tsai HW; Cheng HL; Eisenberger CF; Chow NH J Urol; 2008 Mar; 179(3):1155-9. PubMed ID: 18206169 [TBL] [Abstract][Full Text] [Related]
15. Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia. Lane Z; Epstein JI Am J Surg Pathol; 2008 May; 32(5):758-64. PubMed ID: 18379418 [TBL] [Abstract][Full Text] [Related]
17. [Significance of urinary nuclear matrix protein 22 in diagnosis of transitional cell carcinoma of urinary tract]. Shao Y; Zhuang J; Xu SX; Liu DY Ai Zheng; 2002 Sep; 21(9):1005-7. PubMed ID: 12508552 [TBL] [Abstract][Full Text] [Related]
18. Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma. Luo B; Li W; Deng CH; Zheng FF; Sun XZ; Wang DH; Dai YP Cancer Genet Cytogenet; 2009 Mar; 189(2):93-7. PubMed ID: 19215789 [TBL] [Abstract][Full Text] [Related]
19. ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens. Moatamed NA; Rao JY; Alexanian S; Cobarrubias M; Levin M; Lu D; Apple SK Cancer Cytopathol; 2013 Jun; 121(6):320-8. PubMed ID: 23364848 [TBL] [Abstract][Full Text] [Related]
20. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder. Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]